Lifecore Biomedical, Inc. (LFCR) Stock Forecast
LFCR analyst forecast
as of October 17, 2026- Analyst consensus
- Hold 3.00 / 5 from 4 analysts
- Price target
- $6.28 average of analyst targets
- Upside to target
- −1.6% from the latest close
- Next earnings
- —
- 52-week range
- $3.66 – $8.82
LFCR analyst ratings
4 analystsNumber of analysts at each rating.
LFCR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LFCR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.31 | −$0.33 | −$0.30 | — | — | 3 |
| Current fiscal year (FY2026) | −$1.01 | −$1.05 | −$0.95 | −$0.54 | −86.4% | 3 |
| Next fiscal year (FY2027) | −$0.89 | −$1.08 | −$0.76 | −$1.01 | +11.3% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LFCR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $25.5M | $24.9M | $26.2M | — | 4 |
| Current fiscal year (FY2026) | $121.1M | $120.3M | $122.0M | +60.3% | 4 |
| Next fiscal year (FY2027) | $130.7M | $127.9M | $134.4M | +7.9% | 4 |
LFCR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LFCR revenue: reported and forecast
LFCR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.22 | −$0.22 | −$0.30 | −$0.30 | −$0.31 | +42.5% | 0 up · 0 down |
| Current fiscal year (FY2026) | −$1.04 | −$1.04 | −$1.01 | −$1.01 | −$1.01 | −3.7% | 0 up · 0 down |
| Next fiscal year (FY2027) | −$0.98 | −$0.98 | −$0.88 | −$0.88 | −$0.89 | −9.3% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LFCR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LFCR beat in 7 of 12.
What analysts expect from LFCR
4 analysts cover Lifecore Biomedical; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $6.28, 1.6% below the latest close of $6.38. Analysts expect earnings of −$1.01 per share for FY2026, −86.4% from a year earlier. For FY2027 the average estimate is −$0.89 per share on revenue of $130.7 million. Lifecore Biomedical beat the EPS estimate in 7 of the last 12 quarters.
Related: LFCR income statement, LFCR key metrics, LFCR chart. See the LFCR stock overview for the latest quote and news.
LFCR forecast FAQ
What is Lifecore Biomedical's price target?
The average analyst price target for Lifecore Biomedical is $6.28, 1.6% below the latest close of $6.38.
Is Lifecore Biomedical a buy, hold or sell?
Of 4 analysts covering Lifecore Biomedical, 0 rate it a strong buy, 0 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Lifecore Biomedical's EPS forecast?
Analysts forecast −$1.01 per share for FY2026 (range −$1.05 to −$0.95); for FY2027 the estimate is −$0.89.
What is Lifecore Biomedical's revenue forecast?
The average revenue estimate for FY2026 is $121.1 million, growth of 60.3%; for FY2027 it is $130.7 million.
Does Lifecore Biomedical usually beat earnings estimates?
Lifecore Biomedical reported EPS at or above the analyst estimate in 7 of the last 12 quarters.